Aptose Biosciences reports FY23 EPS ($7.58) vs ($6.80) last yeat

Cash and cash equivalents, January 31 was $18.6M , after gross proceeds from January 2024 financings of $13.7M… Total cash and cash equivalents and investments as of December 31, 2023, were $9.3M a decrease of $37.7 M as compared to $47.M at December 31, 2022. Based on current operations, the Company expects that cash on hand and available capital provide the Company with sufficient resources to fund planned company operations including research and development through August of 2024.R&D expenses increased by $8.7 Mto $36.8M for the year ended December 31 as compared with $28.1M for the comparative period in 2022. Changes to the components of our R&D expenses presented in the table above are primarily related to the following activities:”The data we have generated from tuspetinib thus far – as a single agent and in combination therapy with venetoclax in relapsed and refractory AML – have demonstrated a distinctly favorable safety profile and broad activity for tuspetinib across mutational subtypes. This profile also extends to FLT3 wildtype AML, which represents the majority of AML patients, and in which few agents have shown such broad activity,” said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer. “These data have propelled us to initiate a clinical study of tuspetinib in a triplet combination with venetoclax and azacitidine in frontline therapy for newly diagnosed AML, including both FLT3 wild type and FLT3 mutated subtypes.”